cbdMD Q3 FY2026 Earnings: Revenue Grows 20% as Gross Margin Narrows

cbdMD (NYSE American: YCBD) reported fiscal Q3 2026 net sales of $5.6 million, up 20% from $4.6 million, while diluted loss per share narrowed to $0.11 from $0.21. For the quarter ended June 30, 2026, wholesale growth and the first full-quarter contribution from Bluebird Botanicals lifted revenue, but a weaker sales mix and compliance-related costs reduced gross margin.

Core financial results

Revenue increased faster than gross profit, reflecting a shift toward lower-margin wholesale sales and additional warehouse, repacking, and inventory-reserve costs. Operating expenses also increased, causing the GAAP operating loss to widen even though adjusted EBITDA improved.

The lower per-share loss should be considered alongside an approximately 84% increase in weighted-average shares. GAAP net loss before preferred dividends rose, while lower preferred dividends allowed the loss attributable to common shareholders to narrow slightly.

Adjusted EBITDA is a non-GAAP measure that excludes depreciation and amortization, stock compensation, inventory reserves, regulatory and legal costs, and certain M&A and financing expenses.

Business and channel performance

Direct-to-consumer net sales were $3.9 million, representing 70% of total sales and increasing approximately 9%. Bluebird contributed to the increase, although cbdMD said tighter state-level restrictions offset part of that benefit.

Wholesale net sales rose 61% to $1.7 million and accounted for 30% of revenue. The increase reflected progress at Oasis and the core cbdMD business, making wholesale the faster-growing channel but also contributing to the decline in consolidated gross margin.

Oasis distributor depletions increased 25% during the quarter. The company added South Carolina distribution and changed its Texas distribution partner, more than quadrupling the number of stores with access to the brand. These depletion figures measure distributor product movement rather than recognized revenue.

Bluebird Botanicals generated more than $0.5 million of revenue in its first full quarter under cbdMD. Management expects Bluebird to contribute to both revenue and earnings in fiscal Q4 after creating an integration-related earnings drag during the preceding quarter.

Sales growth did not offset mix pressure and incremental costs

Approximately $947,000 of additional year-over-year sales produced only about $206,000 of additional gross profit. Gross margin fell 6.8 percentage points because of the shift toward wholesale, warehouse and repacking expenses associated with changing state requirements, and a higher inventory reserve ahead of potential regulatory changes.

Operating expenses increased approximately 12% to $4.17 million, outpacing the 7% increase in gross profit. Management cited more than $100,000 of legal and due-diligence expenses related to acquisition opportunities, together with continued product development, clinical work, and regulatory spending.

The adjusted EBITDA improvement therefore diverged from the weaker GAAP operating result. The quarter’s reconciliation included exclusions of $120,000 for an inventory reserve, $53,000 for regulatory and legal matters, and $126,000 for M&A and financing transactions, in addition to depreciation, amortization, and stock compensation.

Cash flow and balance sheet

For the first nine months of fiscal 2026—not the quarter alone—operating cash outflow increased to $1.98 million from $1.21 million. Accounts receivable and inventory consumed cash, with receivables rising to $1.75 million from $1.04 million at the beginning of the fiscal year and inventory increasing to $3.28 million from $2.73 million.

Financing activity largely offset the operating cash use. cbdMD received approximately $2.02 million from preferred stock issuance and about $62,000 from an equity-line draw, leaving cash at $2.12 million on June 30, 2026, compared with $2.26 million on September 30, 2025. Working capital increased to approximately $4.7 million from $3.4 million, but operating cash consumption remained material relative to the cash balance.

Cost-reduction outlook

The company’s quantified forward-looking target focused on expenses. Initiatives implemented in July are intended to reduce supply-chain and other operating costs beginning in fiscal Q4, although the actual savings will depend on execution.

At the upper end, the monthly target is significant relative to the fiscal Q3 adjusted EBITDA loss, but the company had not yet reported realized savings when it released the results.

Pending hemp rules are already affecting costs and inventory decisions

Regulatory uncertainty is influencing cbdMD before new federal rules take effect. Section 781 of H.R. 5371 has a scheduled effective date of November 12, 2026, and the company has already incurred repacking, compliance, and inventory-reserve costs in preparation for possible changes.

A Senate stopgap proposal released in early August would temporarily exempt naturally occurring cannabinoids from the revised total-THC definition and 0.4-milligram-per-container limit through December 11, 2026. As of cbdMD’s August 13 earnings release, the measure still required action by the House, so the extension was not a permanent resolution.

The bipartisan Beverage Regulatory Parity Act would create an alcohol-style framework for hemp-derived beverages, making it directly relevant to Oasis. However, the proposal remained legislation rather than an established regulatory framework.

Recent insider transaction

The provided six-month summary shows no reported insider purchases or sales and approximately 1.12 million total shares held by insiders. Within the two-year transaction history, one transaction includes both a clear sale direction and reported dollar value.

The source also lists director and executive stock awards, but it does not provide share quantities for those grants. Such awards should not be treated as open-market purchases.

Risks investors should monitor

• Gross-margin pressure: Wholesale is growing faster than e-commerce, but the channel mix contributed to a lower gross margin. Additional repacking and inventory-reserve costs could create further pressure.
• Federal and state regulation: State restrictions have already offset some direct-to-consumer growth, while the federal treatment of hemp-derived products remains unresolved. Changes could affect Oasis distribution, product formulations, inventory, and compliance spending.
• Liquidity and financing needs: Nine-month operating cash use approached the June cash balance. Continued losses could require further financing if cost savings and operating improvements do not reduce cash consumption.
• Execution on Bluebird and cost reductions: Management expects Bluebird to contribute to earnings in fiscal Q4 and is targeting substantial monthly savings. Integration costs or delayed savings would weaken the expected improvement.

Summary

cbdMD’s fiscal Q3 2026 revenue growth was driven by wholesale expansion, Oasis distribution, and Bluebird’s first full-quarter contribution. That growth did not translate into better GAAP profitability because gross margin narrowed and operating costs increased, although adjusted EBITDA moved in a more favorable direction. The next operating tests are whether Bluebird becomes earnings-accretive, planned cost reductions materialize, cash use moderates, and pending hemp rules develop into a workable framework.